July 2026 Research Update

This month added something practical: a shared way to describe how active VEXAS inflammation is across the body. The new VEXAS-DAI score is meant to put different organ problems on the same scale, so that future studies can compare people more fairly and track change over time. It is an early step, because the score still needs prospective testing to show how well it matches real-world symptoms and outcomes. [1]

In this work, experts used repeated rounds of structured discussion to agree on 12 organ-system areas to score, with a total score ranging from 0 to 40. They also created scoring rules based on severity grades so that different centers can use the same language when reporting VEXAS activity. Plans were described for future validation, including use in clinical trials. [1]

For patients and caregivers, this mainly matters for future research rather than changing care right now. If the VEXAS-DAI is validated, it could make research results easier to interpret because studies would be using a common yardstick for things like skin, lung, eye, cartilage, and blood-related inflammation. What is still uncertain is how closely this score will match day-to-day symptoms and long-term risks in different people, since that testing has not been reported yet. [1]

This month made clearer that eye inflammation in VEXAS can be more than a local symptom. In a multi-center registry, eye involvement was frequent and it separated a group of patients who, in that dataset, had a higher reported risk of death than those without eye involvement. Many people improved with glucocorticoids (steroids), but not everyone did, and some needed other immune-targeting medicines. [2]

Across 86 people with genetically confirmed VEXAS, ophthalmic inflammation was reported in 41. Eye problems often appeared early in the VEXAS illness, sometimes before the diagnosis was made. The study also reported that relapsing polychondritis (inflammation of cartilage, such as the ears or nose) was more common in those with eye involvement. [2]

When the authors compared outcomes, deaths were reported more often in the group with ophthalmic involvement than in the group without it. They also described that about half of uveitis or scleritis cases had a complete response to steroids, while others only partially improved and some needed additional biologic or small-molecule treatments. The study did not explain why eye involvement tracked with higher mortality, so the link could reflect overall disease severity rather than eye disease itself. [2]

For patients, this adds an important piece to the bigger picture: eye inflammation may be a marker of a more serious overall VEXAS course in at least some groups of patients. This does not prove that eye inflammation causes worse outcomes, but it does clarify that eye symptoms in VEXAS are common and may signal wider inflammation in the body. The uncertainty is how this should be used to predict an individual person's risk, because registry studies cannot fully separate eye involvement from other differences between patients. [2]

This month reinforced how often VEXAS is recognized only after it looks like something else. Several case reports described first presentations that were not obviously "VEXAS," including serious infections and autoimmune-like conditions, followed later by confirmation with UBA1 testing and bone marrow clues. Together, these reports highlight that VEXAS can involve immune overactivity and immune dysfunction at the same time, which can complicate both diagnosis and interpretation of lab tests. [3] [4] [5] [6] [7]

In two reports, infection was central to the early story: one person had biopsy-confirmed Candida infection of the esophagus at initial presentation, and another was diagnosed with VEXAS after Legionella pneumonia. These cases do not show how common infections are in VEXAS, but they do show that infections can be part of the picture and may appear before VEXAS is recognized. [3] [4]

Several cases also highlighted misdiagnosis or delayed diagnosis because the symptoms resembled other inflammatory diseases. One patient carried an adult-onset Still's disease label for 5 years as macrocytic anemia progressed, before UBA1 testing confirmed VEXAS. Another patient was initially treated as ANCA-associated vasculitis before genetic confirmation clarified VEXAS. [5] [6]

A different diagnostic challenge came up when blood tests suggested antiphospholipid syndrome because lupus anticoagulant stayed positive during periods of very high inflammation, even though other antiphospholipid antibodies stayed negative. In that case, VEXAS was confirmed genetically, and the authors emphasized that inflammation and concurrent treatments can complicate interpretation of clotting-related tests. [7]

One report described two different UBA1 Met41 variants in the same person, with very different variant allele frequencies, pointing to "clonal heterogeneity" (more than one mutant cell population). This does not yet tell patients how genetics should guide treatment, but it clarifies that the biology can be more complex than a single mutation result suggests. [8]

Across these cases, inflammatory symptoms often improved when medicines targeting inflammation were used, including prednisone and the IL-6 blocker tocilizumab. Other reports described improvement with ruxolitinib (a JAK inhibitor) in people with difficult skin and joint inflammation, sometimes alongside blood count improvement. One case also reported improvement in blood counts and inflammation after adding azacitidine (a chemotherapy-like drug used in bone marrow disorders) following prednisone. [3] [8] [6] [9] [10] [7] [4]

For patients and caregivers, these reports mainly help set expectations about the diagnostic journey and why it can be confusing. They show that VEXAS can overlap with infections, vasculitis-like illness, Still's disease-like illness, and clotting concerns, and that confirmation often depends on UBA1 testing plus supportive bone marrow findings. The treatment responses described are from single people and cannot predict what will happen for someone else, but they do add to the real-world picture of which symptoms may improve and which problems (like anemia or clotting decisions) can remain complicated. [3] [4] [5] [6] [7] [8] [9] [10]

This month added broader context on where VEXAS fits among diseases caused by mosaic (not-in-every-cell) mutations. In a large referral population tested with deep sequencing, about 1 in 5 diagnosed systemic autoinflammatory disease patients had a mosaic variant, and most of those mosaic cases were VEXAS. This supports the idea that looking for low-level mosaicism can matter in real diagnostic practice, especially in later-onset inflammatory illness. [11]

Among 5,530 referred patients, 403 were diagnosed with a systemic autoinflammatory disease, and mosaic variants were identified in 83 of those diagnosed patients. VEXAS accounted for 69% of the mosaic cases, with other mosaic conditions also found. The study also noted that some mosaic variants were at very low levels (minor allele frequency 5% or less), which is part of why deeper sequencing approaches can be important. [11]

For patients, this is mainly about understanding diagnosis rather than treatment. It clarifies that mosaic genetic changes are not rare among people who ultimately receive an autoinflammatory diagnosis, and that VEXAS is a major part of that mosaic group in referral-center testing. What remains uncertain is how often these results apply outside specialized referral pathways, since the data came from a single national center population and not from the general community. [11]